Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Milestone Pharmaceuticals ( (MIST) ) has shared an announcement.
On December 12, 2025, Milestone Pharmaceuticals announced that the U.S. Food and Drug Administration approved their New Drug Application for CARDAMYST (etripamil) nasal spray, intended for managing paroxysmal supraventricular tachycardia (PSVT). This approval marks a significant milestone for the company, potentially enhancing its market position by offering a novel treatment option that could reduce healthcare costs and empower patients to manage symptomatic attacks effectively.
The most recent analyst rating on (MIST) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Underperform.
Milestone Pharmaceuticals’ overall stock score reflects substantial financial difficulties, including no revenue and negative cash flows. However, the upcoming launch of CARDAMYST provides a potential turnaround opportunity, which is a significant positive factor. Technical indicators suggest a bearish trend, and valuation metrics highlight the lack of earnings and dividends, indicating a speculative investment.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Their primary product is CARDAMYST, a nasal spray designed to manage paroxysmal supraventricular tachycardia (PSVT), a condition characterized by rapid heart rate episodes.
Average Trading Volume: 2,661,282
Technical Sentiment Signal: Buy
Current Market Cap: $205.3M
See more insights into MIST stock on TipRanks’ Stock Analysis page.